迪哲医药11月12日获融资买入1446.18万元，融资余额1.65亿元

Core Viewpoint - Dize Pharmaceutical has shown a significant increase in stock performance and trading activity, with a notable rise in revenue despite a net loss in profit for the year [1][2]. Group 1: Stock Performance - On November 12, Dize Pharmaceutical's stock rose by 3.44%, with a trading volume of 255 million yuan [1]. - The financing buy-in amount on the same day was 14.46 million yuan, while the financing repayment was 15.54 million yuan, resulting in a net financing buy of -1.07 million yuan [1]. - As of November 12, the total financing and securities lending balance was 165 million yuan, which is 0.59% of the circulating market value, indicating a high level compared to the past year [1]. Group 2: Financial Performance - For the period from January to September 2025, Dize Pharmaceutical achieved a revenue of 586 million yuan, representing a year-on-year growth of 73.23% [2]. - The net profit attributable to the parent company was -580 million yuan, reflecting a year-on-year decrease of 3.85% [2]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders increased to 8,806, a rise of 5.01% from the previous period [2]. - The average circulating shares per person increased to 46,528 shares, up by 108.97% [2]. - Notable changes in institutional holdings include Yongying Pharmaceutical Innovation Mixed Fund becoming the fourth largest shareholder, increasing its holdings by 2.30 million shares [2].